Park Kyuhyung, Head of Medical AI Sales at Deepnoid: "Generative AI Drives Innovation in Medical Settings"

"In South Korea, more than 70 million chest X-rays are taken annually. It requires considerable time and effort for radiologists to meticulously review every image and identify all abnormal findings. For this reason, the adoption of artificial intelligence (AI) in medical settings is not a choice, but a necessity."

Park Kyuhyung, Head of Medical AI Sales at Deepnoid, explained the background behind the development of M4CXR, emphasizing the role and potential of M4CXR, a generative AI-based solution for generating chest X-ray interpretation reports.

M4CXR provides findings for a total of 41 chest diseases, including nodules/masses, consolidation, fibrosis, atelectasis, emphysema, tuberculosis, pleural effusion, pneumothorax, cardiomegaly, lymphadenopathy, rib fractures, and diaphragmatic hernia. Deepnoid developed M4CXR to analyze chest X-ray images taken for the purpose of diagnosing and screening chest diseases, enabling AI to independently generate interpretation reports for both normal findings and abnormalities related to chest diseases. Recently, the Ministry of Food and Drug Safety designated M4CXR as an innovative medical device in the advanced technology category.

Park introduced M4CXR as "a solution that goes beyond simply detecting lesions." He added, "AI generates a draft of the interpretation report that medical staff would otherwise have to write themselves, and the vast amount of training data contributes to higher accuracy and reliability." He emphasized that this technology helps reduce the time medical professionals spend on repetitive tasks, allowing them to focus more on patient care.

He also cautioned against the misconception that "AI will replace doctors," clarifying that "M4CXR assists with the verification process that requires significant time and effort from medical staff, thereby reducing their workload."

The development of M4CXR has already been completed through clinical trials and the submission of technical documents. Park stated, "We have submitted the technical documents to the Ministry of Food and Drug Safety, and we expect to obtain domestic regulatory approval within the first quarter of next year."

Park particularly predicted that the effectiveness of M4CXR would be most pronounced in health screening centers. He explained, "Hospitals are places where patients with diseases visit, but screening centers must determine whether a disease is present or not. The key to screening is how accurately 'normal' cases are classified." The more chest X-rays analyzed reliably with M4CXR, the higher the quality of screening services can be.

He also emphasized the need for AI interpretation in emergency situations. "For emergency conditions such as pneumothorax or pleural effusion, time management is extremely important," he said. "There are many cases where same-day interpretation is difficult due to the absence of on-call radiology staff." He explained, "If AI can detect high-risk cases first and alert medical staff, it can help secure critical time to save lives."

원본보기 아이콘

The core factor supporting M4CXR's high accuracy is its vast training data. Park stated, "M4CXR has so far been trained on more than 10 million chest X-ray images and interpretation reports," adding, "Such large-scale datasets play a crucial role in strengthening M4CXR's competitiveness."

He further expressed confidence, saying, "Currently, this is the solution that conducts the most in-depth research on chest diseases in South Korea and can provide draft interpretation reports accordingly."

Deepnoid plans to offer M4CXR not simply as a software subscription, but as an equipment package combined with storage, servers, and portable X-ray devices. He explained, "It is not easy for hospitals to secure a budget for AI adoption, but bundling it with equipment and packages can lower the barrier to entry."

There has also been a positive response to M4CXR in the primary care market. He said, "Since AI interpretation is possible with just a portable X-ray, primary care institutions such as otolaryngology clinics are actively considering adoption."

Deepnoid already has a nationwide sales network and is preparing a roadmap to expand from chest AI to brain imaging and 3D fields.

Interest from overseas medical institutions is also increasing. He explained, "Especially in countries like India, where the number of doctors is low relative to the population, inquiries about M4CXR continue to come in. There is strong demand for AI technology that can fill gaps in medical care."

Concluding the interview, Park once again emphasized the 'golden time' for the generative medical device market. He said, "Chest X-rays are among the most routine examinations, with countless patients undergoing them every day. Applying generative AI to this area will redefine the very standards of medical practice."

Deepnoid plans to actively target overseas markets after obtaining domestic regulatory approval. Park stated, "Next year, we are seeking to collaborate with local companies in Southeast Asia, including Vietnam, the Philippines, and Singapore, to explore local services," adding, "We are also preparing to apply for approval from the United States Food and Drug Administration (FDA)." Deepnoid is pursuing a paid-in capital increase through a rights offering and a general public offering of forfeited shares to accelerate its future growth strategy.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.